SCHEMBL327866

SCHEMBL327866

CCNCCSC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL948604 0.83
SCHEMBL10282534 0.82
SCHEMBL23640297 0.80
SCHEMBL17286045 0.79
SCHEMBL12852149 0.78 CYP2C19 (0.47)
SCHEMBL26645963 0.77
SCHEMBL13562755 0.75
SCHEMBL5002508 0.73
SCHEMBL22695715 0.73
SCHEMBL5634740 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8298744-B2 Coating material for photoresist pattern and method of forming fine pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2012-10-30 US claimed
US-20080286684-A1 COATING MATERIAL FOR PHOTORESIST PATTERN AND METHOD OF FORMING FINE PATTERN USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-11-20 US claimed
WO-2024026433-A2 NOVEL DPP1 INHIBITORS AND USES THEREOF INSMED INCORPORATED (US) 2024-02-01 WO disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
WO-2023223097-A1 ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2023-11-23 WO disclosed
WO-2023225320-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
WO-2023225359-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
WO-2023225336-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
US-20230338310-A1 ANTI-VIRAL THERAPY NOVABIOTICS LIMITED (GB) 2023-10-26 US disclosed
EP-3675809-B1 USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS BASF SE (DE) 2023-09-27 EP disclosed
EP-3675809-B1 USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS BASF SE (DE) 2023-09-27 EP disclosed
WO-2017034367-A2 COMPOSITION FOR SURFACE MODIFICATION 주식회사 엘지생활건강 2017-03-02 WO disclosed
US-20160311853-A1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2016-10-27 US disclosed
US-8298744-B2 Coating material for photoresist pattern and method of forming fine pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2012-10-30 US disclosed
US-8133894-B2 N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones AKEBIA THERAPEUTICS INC. (US) 2012-03-13 US disclosed
US-20100305097-A1 N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES WARNER CHILCOTT COMPANY, LLC 2010-12-02 US disclosed
EP-2103611-A1 BENZOXAZOLE DERIVATIVES Tohoku University (JP) 2009-09-23 EP disclosed
WO-2009057827-A1 PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-07 WO disclosed
US-20080286684-A1 COATING MATERIAL FOR PHOTORESIST PATTERN AND METHOD OF FORMING FINE PATTERN USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-11-20 US disclosed
US-20040097560-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY 2004-05-20 US disclosed